Polaryx Therapeutics Inc
Research Polaryx Therapeutics Inc (PLYX) on Bullrun: market cap USD 99.19M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPLYX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 99.19M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 6.48M
- Free cash flow-USD 5.30M
Valuation Snapshot
latest market cap is USD 99.19M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 8.99M | -USD 3.94M | n/a | -0.2 | USD 5.14M | n/a | USD 4.57M |
| FY2024 | n/a | -USD 30.36M | n/a | n/a | -0.89 | USD 4.62M | n/a | USD 4.71M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 99.19M | n/a | n/a | n/a |
About Polaryx Therapeutics Inc
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Polaryx Therapeutics Inc's market cap?
Polaryx Therapeutics Inc's market capitalization is USD 99.19M.
What does Polaryx Therapeutics Inc do?
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.